Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Imagine a stock rising a whopping 46,000%, when the company makes no revenue! As unbelievable as it sounds, that’s the case for a herbal medicine biotech company. The shares of Regencell ...

Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They issued a “buy” rating and a $135.00 target price for the company.

Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics The move fuses a ‘delivery’ company with a ‘cargo’ company Adobe By Jason Mast Dec. 11, 2024 ...

Gufic Biosciences Q1 Results Live : Gufic Biosciences declared their Q1 results on 14 Aug, 2024. The company reported a revenue increase of 4% year-over-year (YoY) and a profit increase of 1.13% YoY.

Blueprint Medicines became the first company to offer a precision treatment for ISM in May 2023, when the FDA approved Ayvakit (avapritinib). First approved in 2021 to treat more aggressive mast ...

In recognizing Insilico Medicine’s selection as 2024’s top biotech company, Fast Company writes that “In 2023, it was hard to escape the hype around AI, regardless of the industry.

Gufic Biosciences gains on Aussie, Brazilian nod to pain-killer drug "The medicine will be used for short-term treatment of acute pain and post-operative pain in adult patients,” the company ...

Gufic Biosciences Limited’s shares were up by 2.31 per cent after the company received approvals from the Therapeutic Group Administration (TGA) in Australia and the National Health Surveillance ...